Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | -6.47% | 149.71 | 0.0% | $1388.80m | |
| NVAX | Novavax, Inc. | -10.27% | 75.96 | 78.2% | $521.47m | |
| AMGN | Amgen, Inc. | -2.25% | 222.59 | 1.4% | $501.20m | |
| BIIB | Biogen, Inc. | 0.22% | 221.01 | 1.8% | $497.88m | |
| GILD | Gilead Sciences, Inc. | -1.42% | 67.54 | 1.0% | $485.06m | |
| BNTX | BioNTech SE | -0.37% | 146.95 | 0.0% | $411.97m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -1.36% | 612.95 | 2.7% | $397.26m | |
| ILMN | Illumina, Inc. | -2.20% | 357.90 | 3.3% | $370.53m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -0.52% | 226.90 | 1.9% | $339.19m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | 1.13% | 2.68 | 0.7% | $187.34m | |
| EXAS | EXACT Sciences Corp. | -2.38% | 72.27 | 17.9% | $164.65m | |
| ARNA | Arena Pharmaceuticals, Inc. | -0.66% | 89.88 | 13.7% | $130.50m | |
| INCY | Incyte Corp. | -0.63% | 74.32 | 2.4% | $129.36m | |
| ALNY | Alnylam Pharmaceuticals, Inc. | -1.33% | 134.60 | 8.2% | $123.34m | |
| BMRN | BioMarin Pharmaceutical, Inc. | 0.07% | 84.71 | 4.2% | $103.25m |
Company Profile
Monopar Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The firm engages in building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages. Its product pipeline includes Validive, Camsirubicin and MNPR-101. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.